ACADIA PHARMACEUTICALS INC. Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
ACADIA PHARMACEUTICALS INC. (ACAD) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $32.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2015-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2015-02-26
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2012-12-31 was $4.00K, a 55.56% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2012-09-30 was $9.00K, a 25.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2012-06-30 was $10.00K.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2012-03-31 was $9.00K.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2012 was $32.00K, a 58.97% decline from fiscal 2011.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2011 was $78.00K, a 77.90% decline from fiscal 2010.
- ACADIA PHARMACEUTICALS INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2010 was $353.00K.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month |
|---|---|---|---|---|
| 2012-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $13.00K derived: sum of 2 quarters · filed 2015-02-26 | $23.00K derived: sum of 3 quarters · filed 2015-02-26 | $32.00K 10-K · filed 2015-02-26 |
| 2012-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $19.00K derived: sum of 2 quarters · filed 2013-11-06 | $28.00K 10-Q · filed 2013-11-06 | $37.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $19.00K 10-Q · filed 2013-08-06 | $28.00K derived: sum of 3 quarters · filed 2014-02-27 | $40.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $9.00K 10-Q · filed 2013-05-07 | $18.00K derived: sum of 2 quarters · filed 2014-02-27 | $30.00K derived: sum of 3 quarters · filed 2014-02-27 | |
| 2011-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $21.00K derived: sum of 2 quarters · filed 2014-02-27 | $78.00K 10-K · filed 2014-02-27 | |
| 2011-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $69.00K 10-Q · filed 2012-11-05 | ||
| 2011-06-30 | $57.00K 10-Q · filed 2012-08-08 | |||
| 2010-12-31 | $353.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |